Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 30, 2021
Business Overview: Akebia is a biopharmaceutical company focused on developing therapies for chronic kidney disease. This filing reports a significant regulatory milestone regarding its lead investigational drug, vadadustat.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat. Key details include:
- Drug: Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
- Indication: Treatment of anemia due to chronic kidney disease in adult patients on dialysis and adult patients not on dialysis.
- Regulatory Timeline: The FDA has a standard 60-day period to determine if the NDA is complete and acceptable for review.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the NDA submission. The company notes the standard FDA review timeline for acceptance.
Risks and Contingencies: The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other SEC filings. This limits the legal liability of the forward-looking statements contained within the press release.
Investor Verification Checklist
- Verify the FDA's determination on the completeness of the NDA within the 60-day review window.
- Review the full text of the press release (Exhibit 99.1) for specific clinical data supporting the NDA submission.
- Monitor subsequent filings for the FDA's acceptance letter or any requests for additional information.
- Check the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not provide financial status.